- CA$10.44m
- CA$4.99m
- CA$21.69m
- 43
- 71
- 45
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.53 | ||
| Price to Tang. Book | 1.34 | ||
| Price to Free Cashflow | 14.56 | ||
| Price to Sales | 0.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.11% | ||
| Return on Equity | -12.9% | ||
| Operating Margin | -12.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 20.17 | 11.61 | 21.74 | 23.07 | 21.69 | n/a | n/a | -5.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.
Directors
- Albert Friesen CHM (74)
- Neil Owens PRE
- David Gurvey CFO
- Brent Fawkes IND (51)
- Manon Harvey IND
- Gerald McDole IND (81)
- Arnold Naimark IND (87)
- Peter Quick IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 23rd, 2000
- Public Since
- March 30th, 1999
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 10,436,313
- Address
- 1250 Waverley Street, WINNIPEG, R3T 6C6
- Web
- https://www.medicure.com/
- Phone
- +1 2044877412
- Auditors
- Ernst & Young LLP
Upcoming Events for MPH
Similar to MPH
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Kane Biotech
TSX Venture Exchange
KDA
TSX Venture Exchange
FAQ
What is the Medicure share price?
As of Today at 21:58 UTC, shares in Medicure are trading at CA$1.00. This share price information is delayed by 15 minutes.
How has the Medicure share price performed this year?
Shares in Medicure last closed at CA$1.00 and the price had moved by -28.87% over the past 365 days. In terms of relative price strength the Medicure share price has underperformed the Toronto Stock Exchange 300 Composite Index by -37.32% over the past year.
What are the analyst and broker recommendations for Medicure?
The overall consensus recommendation for Medicure is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medicure dividend yield?
Medicure does not currently pay a dividend.
Does Medicure pay a dividend?
Medicure does not currently pay a dividend.
When does Medicure next pay dividends?
Medicure does not currently pay a dividend.
How do I buy Medicure shares?
To buy shares in Medicure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medicure?
As of the previous close price of CA$1.00, shares in Medicure had a market capitalisation of CA$10.44m.
Where are Medicure shares listed?
Here are the trading details for Medicure:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: MPH
What kind of share is Medicure?
Based on an overall assessment of its quality, value and momentum Medicure is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medicure share price forecast for 2024?
The analyst consensus target price for shares in Medicure is CA$2.80. That is 180% above the last closing price of CA$1.00.
Analysts covering Medicure currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Medicure share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicure. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -14.59%.
As of the last closing price of CA$1.00, shares in Medicure were trading -21.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medicure PE Ratio?
The Medicure PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medicure?
Medicure's management team is headed by:
- Albert Friesen - CHM
- Neil Owens - PRE
- David Gurvey - CFO
- Brent Fawkes - IND
- Manon Harvey - IND
- Gerald McDole - IND
- Arnold Naimark - IND
- Peter Quick - IND